The role of mGluR5 on the therapeutic effects of ketamine in Wistar rats.

Anxiety Behavioral despair CDPPB EPM FST Fear Ketamine MTEP OFT mGluR5

Journal

Psychopharmacology

ISSN: 1432-2072

Titre abrégé: Psychopharmacology (Berl)

Pays: Germany

ID NLM: 7608025

Informations de publication

Date de publication:
09 Mar 2024

Historique:

received: 27 11 2023

accepted: 04 03 2024

medline: 9 3 2024

pubmed: 9 3 2024

entrez: 9 3 2024

Statut: aheadofprint

Résumé

Ketamine produces dissociative, psychomimetic, anxiolytic, antidepressant, and anesthetic effects in a dose dependent manner. It has a complex mechanism of action that involve alterations in other glutamate receptors. The metabotropic glutamate receptor 5 (mGluR5) has been investigated in relation to the psychotic and anesthetic properties of ketamine, while its role in mediating the therapeutic effects of ketamine remains unknown. We investigated the role of mGluR5 on the antidepressant, anxiolytic and fear memory-related effects of ketamine in adult male Wistar rats. Two sets of experiments were conducted. We first utilized the positive allosteric modulator CDPPB to investigate how acute mGluR5 activation regulates the therapeutic effects of ketamine (10 mg/kg). We then tested the synergistic antidepressant effect of mGluR5 antagonism and ketamine by combining MTEP with a sub-effective dose of ketamine (1 mg/kg). Behavioral despair, locomotor activity, anxiety-like behavior, and fear memory were respectively assessed in the forced swim test (FST), open field test (OFT), elevated plus maze (EPM), and auditory fear conditioning. Enhancing mGluR5 activity via CDPPB occluded the antidepressant effect of ketamine without changing locomotor activity. Furthermore, concomitant administration of MTEP and ketamine exhibited a robust synergistic antidepressant effect. The MTEP + ketamine treatment, however, blocked the anxiolytic effect observed by sole administration of MTEP or the low dose ketamine. These findings suggest that suppressed mGluR5 activity is required for the antidepressant effects of ketamine. Consequently, the antagonism of mGluR5 enhances the antidepressant effectiveness of low dose ketamine, but eliminates its anxiolytic effects.

Identifiants

DOI: 10.1007/s00213-024-06571-3 PMID: 38459971

pubmed: 38459971

doi: 10.1007/s00213-024-06571-3

pii: 10.1007/s00213-024-06571-3

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Boğaziçi Üniversitesi

ID : 22B07P1

Informations de copyright

Références

Akan M, Skorodumov I, Meinhardt MW, Canbeyli R, Unal G (2023) A shea butter-based ketamine ointment: The antidepressant effects of transdermal ketamine in rats. Behav Brain Res 452:114594. https://doi.org/10.1016/j.bbr.2023.114594

doi: 10.1016/j.bbr.2023.114594 pubmed: 37487837

Alagarsamy S, Marino MJ, Rouse ST, Gereau RW, Heinemann SF, Conn PJ (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2(3):234–240. https://doi.org/10.1038/6338

doi: 10.1038/6338 pubmed: 10195215

Alagarsamy S, Rouse ST, Junge C, Hubert GW, Gutman D, Smith Y, Conn PJ (2002) NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol Biochem Behav 73(2):299–306. https://doi.org/10.1016/S0091-3057(02)00826-2

doi: 10.1016/S0091-3057(02)00826-2 pubmed: 12117583

Alagarsamy S, Saugstad J, Warren L, Mansuy IM, Gereau RW, Conn PJ (2005) NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology 49:135–145. https://doi.org/10.1016/j.neuropharm.2005.05.005

doi: 10.1016/j.neuropharm.2005.05.005 pubmed: 16005030 pmcid: 3799794

Aleksandrova LR, Phillips AG, Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci 42(4):222–229. https://doi.org/10.1503/jpn.160175

doi: 10.1503/jpn.160175 pubmed: 28234212 pmcid: 5487269

Amiri S, Haj-Mirzaian A, Rahimi-Balaei M, Razmi A, Kordjazy N, Shirzadian A, Ejtemaei Mehr S, Sianati H, Dehpour AR (2015) Co-occurrence of anxiety and depressive-like behaviors following adolescent social isolation in male mice; possible role of nitrergic system. Physiol Behav 145:38–44. https://doi.org/10.1016/j.physbeh.2015.03.032

doi: 10.1016/j.physbeh.2015.03.032 pubmed: 25817356

Anchan D, Clark S, Pollard K, Vasudevan N (2014) GPR30 activation decreases anxiety in the open field test but not in the elevated plus maze test in female mice. Brain and Behavior 4(1):51–59. https://doi.org/10.1002/brb3.197

doi: 10.1002/brb3.197 pubmed: 24653954

Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, Akhondzadeh S (2018) Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord 235:236–241. https://doi.org/10.1016/j.jad.2018.02.056

doi: 10.1016/j.jad.2018.02.056 pubmed: 29660637

Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20(21):7871–7879. https://doi.org/10.1523/JNEUROSCI.20-21-07871.2000

doi: 10.1523/JNEUROSCI.20-21-07871.2000 pubmed: 11050106 pmcid: 6772731

Belozertseva I, Kos T, Popik P, Danysz W, Bespalov A (2007) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 17(3):172–179. https://doi.org/10.1016/j.euroneuro.2006.03.002

doi: 10.1016/j.euroneuro.2006.03.002 pubmed: 16630709

Benquet P, Gee CE, Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22(22):9679–9686. https://doi.org/10.1523/JNEUROSCI.22-22-09679.2002

doi: 10.1523/JNEUROSCI.22-22-09679.2002 pubmed: 12427823 pmcid: 6757830

Bertaso F, Roussignol G, Worley P, Bockaert J, Fagni L, Ango F (2010) Homer1a-dependent crosstalk between NMDA and metabotropic glutamate receptors in mouse neurons. PLoS ONE 5(3):e9755. https://doi.org/10.1371/journal.pone.0009755

doi: 10.1371/journal.pone.0009755 pubmed: 20305784 pmcid: 2841198

Bockaert J, Perroy J, Ango F (2021) The complex formed by group I Metabotropic Glutamate Receptor (mGluR) and Homer1a plays a central role in metaplasticity and homeostatic synaptic scaling. J Neurosci 41(26):5567–5578. https://doi.org/10.1523/JNEUROSCI.0026-21.2021

doi: 10.1523/JNEUROSCI.0026-21.2021 pubmed: 34193623 pmcid: 8244974

Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA (2002) Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 16(11):2241–2244. https://doi.org/10.1046/j.1460-9568.2002.02294.x

doi: 10.1046/j.1460-9568.2002.02294.x pubmed: 12473093

Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004) The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiat 55(12):1171–1178. https://doi.org/10.1016/j.biopsych.2004.02.029

doi: 10.1016/j.biopsych.2004.02.029 pubmed: 15184036

Carreno FR, Donegan JJ, Boley AM, Shah A, DeGuzman M, Frazer A, Lodge DJ (2016) Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21(9):1298–1308. https://doi.org/10.1038/mp.2015.176

doi: 10.1038/mp.2015.176 pubmed: 26619811

Castro CA, Hogan JB, Benson KA, Shehata CW, Landauer MR (1995) Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80, and emulphor-620. Pharmacol Biochem Behav 50(4):521–526. https://doi.org/10.1016/0091-3057(94)00331-9

doi: 10.1016/0091-3057(94)00331-9 pubmed: 7617697

Chaki S, Watanabe M (2023) Antidepressants in the post-ketamine era: Pharmacological approaches targeting the glutamatergic system. Neuropharmacology 223:109348. https://doi.org/10.1016/j.neuropharm.2022.109348

doi: 10.1016/j.neuropharm.2022.109348 pubmed: 36423706

Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A (2013) mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology 66:40–52. https://doi.org/10.1016/j.neuropharm.2012.05.022

doi: 10.1016/j.neuropharm.2012.05.022 pubmed: 22640631

Chan M-H, Chiu P-H, Sou J-H, Chen H-H (2008) Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology 198(1):141–148. https://doi.org/10.1007/s00213-008-1103-1

doi: 10.1007/s00213-008-1103-1 pubmed: 18311557

Chen H-H, Liao P-F, Chan M-H (2011) mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci 18(1):19. https://doi.org/10.1186/1423-0127-18-19

doi: 10.1186/1423-0127-18-19 pubmed: 21342491 pmcid: 3050796

Choi M, Lee SH, Chang HL, Son H (2016) Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats. Biochim Biophys Acta (BBA) - Mol Basis Dis 1862(7):1247–1254. https://doi.org/10.1016/j.bbadis.2016.04.001

doi: 10.1016/j.bbadis.2016.04.001

Choi KH, Berman RY, Zhang M, Spencer HF, Radford KD (2020) Effects of ketamine on rodent fear memory. Int J Mol Sci 21(19):7173. https://doi.org/10.3390/ijms21197173

doi: 10.3390/ijms21197173 pubmed: 32998470 pmcid: 7582895

Clifton NE, Trent S, Thomas KL, Hall J (2019) Regulation and function of activity-dependent homer in synaptic plasticity. Complex Psychiatry 5(3):147–161. https://doi.org/10.1159/000500267

doi: 10.1159/000500267

Cooper MD, Rosenblat JD, Cha DS, Lee Y, Kakar R, McIntyre RS (2017) Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. World J Biol Psychiatry 18(6):410–423. https://doi.org/10.3109/15622975.2016.1139747

doi: 10.3109/15622975.2016.1139747 pubmed: 26752601

Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29(4–5):547–569. https://doi.org/10.1016/j.neubiorev.2005.03.008

doi: 10.1016/j.neubiorev.2005.03.008 pubmed: 15893822

de Bartolomeis A, Sarappa C, Buonaguro EF, Marmo F, Eramo A, Tomasetti C, Iasevoli F (2013) Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog Neuropsychopharmacol Biol Psychiatry 46:1–12. https://doi.org/10.1016/j.pnpbp.2013.06.010

doi: 10.1016/j.pnpbp.2013.06.010 pubmed: 23800465

DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I (2015) In Vivo Ketamine-Induced Changes in [11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Biol Psychiat 77(3):266–275. https://doi.org/10.1016/j.biopsych.2014.06.024

doi: 10.1016/j.biopsych.2014.06.024 pubmed: 25156701

Deyama S, Bang E, Wohleb ES, Li X-Y, Kato T, Gerhard DM, Dutheil S, Dwyer JM, Taylor SR, Picciotto MR, Duman RS (2019) Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. Am J Psychiatry 176(5):388–400. https://doi.org/10.1176/appi.ajp.2018.17121368

doi: 10.1176/appi.ajp.2018.17121368 pubmed: 30606046 pmcid: 6494682

Domin H, Szewczyk B, Woźniak M, Wawrzak-Wleciał A, Śmiałowska M (2014) Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behav Brain Res 273:23–33. https://doi.org/10.1016/j.bbr.2014.07.019

doi: 10.1016/j.bbr.2014.07.019 pubmed: 25043733

Ecevitoglu A, Canbeyli R, Unal G (2019) Oral ketamine alleviates behavioral despair without cognitive impairment in Wistar rats. Behav Brain Res 372:112058. https://doi.org/10.1016/j.bbr.2019.112058

doi: 10.1016/j.bbr.2019.112058 pubmed: 31247234

Engin E, Treit D, Dickson CT (2009) Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 161(2):359–369. https://doi.org/10.1016/j.neuroscience.2009.03.038

doi: 10.1016/j.neuroscience.2009.03.038 pubmed: 19321151

Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C (2018) Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry 23(4):824–832. https://doi.org/10.1038/mp.2017.58

doi: 10.1038/mp.2017.58 pubmed: 28397841

Fraser LM, Brown RE, Hussin A, Fontana M, Whittaker A, O’Leary TP, Lederle L, Holmes A, Ramos A (2010) Measuring anxiety- and locomotion-related behaviours in mice: a new way of using old tests. Psychopharmacology 211(1):99–112. https://doi.org/10.1007/s00213-010-1873-0

doi: 10.1007/s00213-010-1873-0 pubmed: 20454890

Fukumoto K, Iijima M, Chaki S (2016) The Antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41(4):1046–1056. https://doi.org/10.1038/npp.2015.233

doi: 10.1038/npp.2015.233 pubmed: 26245499

Garcia LSB, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32(1):140–144. https://doi.org/10.1016/j.pnpbp.2007.07.027

doi: 10.1016/j.pnpbp.2007.07.027 pubmed: 17884272

Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, Taylor SR, Duman CH, Delpire E, Picciotto M, Wohleb ES, Duman RS (2020) GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Investig 130(3):1336–1349. https://doi.org/10.1172/JCI130808

doi: 10.1172/JCI130808 pubmed: 31743111 pmcid: 7269589

Girgenti MJ, Ghosal S, LoPresto D, Taylor JR, Duman RS (2017) Ketamine accelerates fear extinction via mTORC1 signaling. Neurobiol Dis 100:1–8. https://doi.org/10.1016/j.nbd.2016.12.026

doi: 10.1016/j.nbd.2016.12.026 pubmed: 28043916

Gravius A, Barberi C, Schäfer D, Schmidt WJ, Danysz W (2006) The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats – a comparison. Neuropharmacology 51(7–8):1146–1155. https://doi.org/10.1016/j.neuropharm.2006.07.008

doi: 10.1016/j.neuropharm.2006.07.008 pubmed: 16905160

Henry S (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43(8):1199–1209. https://doi.org/10.1016/S0028-3908(02)00332-5

doi: 10.1016/S0028-3908(02)00332-5 pubmed: 12527469

Hetzler BE, Swain Wautlet B (1985) Ketamine-induced locomotion in rats in an open-field. Pharmacol Biochem Behav 22(4):653–655. https://doi.org/10.1016/0091-3057(85)90291-6

doi: 10.1016/0091-3057(85)90291-6 pubmed: 3991775

Holz A, Mülsch F, Schwarz MK, Hollmann M, Döbrössy MD, Coenen VA, Bartos M, Normann C, Biber K, van Calker D, Serchov T (2019) Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepressant effects via AMPA receptor activation. Neuron 104(2):338-352.e7. https://doi.org/10.1016/j.neuron.2019.07.011

doi: 10.1016/j.neuron.2019.07.011 pubmed: 31420117

Horsley RR, Páleníček T, Kolin J, Valeš K (2018) Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. Behav Pharmacol 29(6):530–536. https://doi.org/10.1097/FBP.0000000000000394

doi: 10.1097/FBP.0000000000000394 pubmed: 29537989

Jesse CR, Bortolatto CF, Savegnago L, Rocha JB, Nogueira CW (2008) Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 32(8):1838–1843. https://doi.org/10.1016/j.pnpbp.2008.08.010

doi: 10.1016/j.pnpbp.2008.08.010 pubmed: 18773934

Jin D, Guo M, Xue B, Mao L, Wang JQ (2013) Differential regulation of CaMKIIα interactions with mGluR5 and NMDA receptors by Ca(2+) in neurons. J Neurochem 127(5):620–631. https://doi.org/10.1111/jnc.12434

doi: 10.1111/jnc.12434 pubmed: 24032403 pmcid: 3933469

Kim J-W, Suzuki K, Kavalali ET, Monteggia LM (2023) Bridging rapid and sustained antidepressant effects of ketamine. Trends Mol Med 29(5):364–375. https://doi.org/10.1016/j.molmed.2023.02.003

doi: 10.1016/j.molmed.2023.02.003 pubmed: 36907686

Kingir E, Sevinc C, Unal G (2023) Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress. Neuropharmacology 228:109468. https://doi.org/10.1016/j.neuropharm.2023.109468

doi: 10.1016/j.neuropharm.2023.109468 pubmed: 36813161

Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111–115. https://doi.org/10.1016/j.bbr.2014.05.065

doi: 10.1016/j.bbr.2014.05.065 pubmed: 24909673

Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224(1):107–111. https://doi.org/10.1016/j.bbr.2011.05.035

doi: 10.1016/j.bbr.2011.05.035 pubmed: 21669235

Kokras N, Polissidis A, Antoniou K, Dalla C (2017) Head shaking in the forced swim test: A robust but unexplored sex difference. Pharmacol Biochem Behav 152:90–96. https://doi.org/10.1016/j.pbb.2016.05.007

doi: 10.1016/j.pbb.2016.05.007 pubmed: 27184928

Konieczny J, Ossowska K, Wolfarth S, Pilc A (1998) LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol 358(4):500–502. https://doi.org/10.1007/pl00005284

doi: 10.1007/pl00005284 pubmed: 9826074

Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS (2010) Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24(8):669–693. https://doi.org/10.2165/11533230-000000000-00000

doi: 10.2165/11533230-000000000-00000 pubmed: 20658799

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214. https://doi.org/10.1001/archpsyc.1994.03950030035004

Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiat 76(12):970–976. https://doi.org/10.1016/j.biopsych.2014.03.026

doi: 10.1016/j.biopsych.2014.03.026 pubmed: 24821196

Lea PM, Faden AI (2006) Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 12(2):149–166. https://doi.org/10.1111/j.1527-3458.2006.00149.x

doi: 10.1111/j.1527-3458.2006.00149.x pubmed: 16958988 pmcid: 6494124

Lee K-W, Westin L, Kim J, Chang JC, Oh Y-S, Amreen B, Gresack J, Flajolet M, Kim D, Aperia A, Kim Y, Greengard P (2015) Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry 20(12):1546–1556. https://doi.org/10.1038/mp.2015.132

doi: 10.1038/mp.2015.132 pubmed: 26370144 pmcid: 4907335

Li Y, Zhu ZR, Ou BC, Wang YQ, Tan ZB, Deng CM, Gao YY, Tang M, So JH, Mu YL, Zhang LQ (2015) Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behav Brain Res 279:100–105. https://doi.org/10.1016/j.bbr.2014.11.016

doi: 10.1016/j.bbr.2014.11.016 pubmed: 25449845

Li X, Du ZJ, Xu JN, Liang ZM, Lin S, Chen H, Li SJ, Li XW, Yang JM, Gao TM (2023) mGluR5 in hippocampal CA1 pyramidal neurons mediates stress-induced anxiety-like behavior. Neuropsychopharmacology 48(8):1164–1174. https://doi.org/10.1038/s41386-023-01548-w

doi: 10.1038/s41386-023-01548-w pubmed: 36797374

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, … Jaeschke G (2015) Pharmacology of Basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther 353(1):213–233. https://doi.org/10.1124/jpet.114.222463

Liu R-J, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK (2013) GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38(11):2268–2277. https://doi.org/10.1038/npp.2013.128

doi: 10.1038/npp.2013.128 pubmed: 23680942 pmcid: 3773678

Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic acid receptors. Biol Psychiat 63(4):349–352. https://doi.org/10.1016/j.biopsych.2007.05.028

doi: 10.1016/j.biopsych.2007.05.028 pubmed: 17643398

Matta JA, Ashby MC, Sanz-Clemente A, Roche KW, Isaac JTR (2011) mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron 70(2):339–351. https://doi.org/10.1016/j.neuron.2011.02.045

doi: 10.1016/j.neuron.2011.02.045 pubmed: 21521618 pmcid: 3087383

Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50(1):295–322. https://doi.org/10.1146/annurev.pharmtox.011008.145533

doi: 10.1146/annurev.pharmtox.011008.145533 pubmed: 20055706 pmcid: 2904507

Pałucha A, Brański P, Szewczyk B, Wierońska JM, Kłak K, Pilc A (2005) Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 81(4):901–906. https://doi.org/10.1016/j.pbb.2005.06.015

doi: 10.1016/j.pbb.2005.06.015 pubmed: 16040106

Pałucha-Poniewiera A, Podkowa K, Pilc A (2019) Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. Behav Pharmacol 30(6):471–477. https://doi.org/10.1097/FBP.0000000000000471

doi: 10.1097/FBP.0000000000000471 pubmed: 30724804

Pennington ZT, Dong Z, Feng Y, Vetere LM, Page-Harley L, Shuman T, Cai DJ (2019) ezTrack: An open-source video analysis pipeline for the investigation of animal behavior. Sci Rep 9(1):19979. https://doi.org/10.1038/s41598-019-56408-9

doi: 10.1038/s41598-019-56408-9 pubmed: 31882950 pmcid: 6934800

Pietraszek M, Gravius A, Schäfer D, Weil T, Trifanova D, Danysz W (2005a) mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49(1):73–85. https://doi.org/10.1016/j.neuropharm.2005.01.027

doi: 10.1016/j.neuropharm.2005.01.027 pubmed: 15992582

Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W (2005b) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514(1):25–34. https://doi.org/10.1016/j.ejphar.2005.03.028

doi: 10.1016/j.ejphar.2005.03.028 pubmed: 15878321

Piva A, Caffino L, Padovani L, Pintori N, Mottarlini F, Sferrazza G, Paolone G, Fumagalli F, Chiamulera C (2020) The metaplastic effects of ketamine on sucrose renewal and contextual memory reconsolidation in rats. Behav Brain Res 379:112347. https://doi.org/10.1016/j.bbr.2019.112347

doi: 10.1016/j.bbr.2019.112347 pubmed: 31706797

Podkowa K, Pochwat B, Brański P, Pilc A, Pałucha-Poniewiera A (2016) Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology 233(15–16):2901–2914. https://doi.org/10.1007/s00213-016-4325-7

doi: 10.1007/s00213-016-4325-7 pubmed: 27286960 pmcid: 4933730

Pomierny-Chamioło L, Poleszak E, Pilc A, Nowak G (2010) NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep 62(6):1186–1190. https://doi.org/10.1016/S1734-1140(10)70381-9

doi: 10.1016/S1734-1140(10)70381-9 pubmed: 21273676

Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266(5604):730–732. https://doi.org/10.1038/266730a0

doi: 10.1038/266730a0 pubmed: 559941

Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463(1–3):3–33. https://doi.org/10.1016/s0014-2999(03)01272-x

doi: 10.1016/s0014-2999(03)01272-x pubmed: 12600700

Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M, Parkar N, Fontoura P, Santarelli L (2016) Efficacy and safety of Basimglurant as adjunctive therapy for major depression: A randomized clinical trial. JAMA Psychiat 73(7):675–684. https://doi.org/10.1001/jamapsychiatry.2016.0838

doi: 10.1001/jamapsychiatry.2016.0838

Radford KD, Park TY, Jaiswal S, Pan H, Knutsen A, Zhang M, Driscoll M, Osborne-Smith LA, Dardzinski BJ, Choi KH (2018) Enhanced fear memories and brain glucose metabolism (18F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats. Transl Psychiatry 8(1):263. https://doi.org/10.1038/s41398-018-0310-8

doi: 10.1038/s41398-018-0310-8 pubmed: 30504810 pmcid: 6269482

Razoux F, Garcia R, Léna I (2007) Ketamine, at a Dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 32(3):719–727. https://doi.org/10.1038/sj.npp.1301057

doi: 10.1038/sj.npp.1301057 pubmed: 16525415

Romano C, Sesma MA, McDonald CT, O’malley K, van den Pol AN, Olney JW (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355(3):455–469. https://doi.org/10.1002/cne.903550310

doi: 10.1002/cne.903550310 pubmed: 7636025

Serchov T, Clement H-W, Schwarz MK, Iasevoli F, Tosh DK, Idzko M, Jacobson KA, de Bartolomeis A, Normann C, Biber K, van Calker D (2015) Increased signaling via adenosine A1 receptors, sleep deprivation, imipramine, and ketamine inhibit depressive-like behavior via induction of homer1a. Neuron 87(3):549–562. https://doi.org/10.1016/j.neuron.2015.07.010

doi: 10.1016/j.neuron.2015.07.010 pubmed: 26247862 pmcid: 4803038

Sethna F, Wang H (2014) Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction. Learn Mem 21(12):647–650. https://doi.org/10.1101/lm.035857.114

doi: 10.1101/lm.035857.114 pubmed: 25403451 pmcid: 4236415

Silote GP, de Oliveira SFS, Ribeiro DE, Machado MS, Andreatini R, Joca SRL, Beijamini V (2020) Ketamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings. Prog Neuropsychopharmacol Biol Psychiatry 100:109878. https://doi.org/10.1016/j.pnpbp.2020.109878

doi: 10.1016/j.pnpbp.2020.109878 pubmed: 31982463

Sofia RD, Harakal JD (1975) Evaluation of ketamine HCl for anti-depressant activity. Arch Int Pharmacodyn Ther 214(1):68–74

pubmed: 1156026

Sou J-H, Chan M-H, Chen H-H (2006) Ketamine, but not propofol, anaesthesia is regulated by metabotropic glutamate 5 receptors. Br J Anaesth 96(5):597–601. https://doi.org/10.1093/bja/ael046

doi: 10.1093/bja/ael046 pubmed: 16531447

Sturman O, Germain P-L, Bohacek J (2018) Exploratory rearing: a context- and stress-sensitive behavior recorded in the open-field test. Stress 21(5):443–452. https://doi.org/10.1080/10253890.2018.1438405

doi: 10.1080/10253890.2018.1438405 pubmed: 29451062

Su LD, Wang N, Han J, Shen Y (2022) Group 1 Metabotropic glutamate receptors in neurological and psychiatric diseases: Mechanisms and prospective. Neuroscientist 28(5):453–468. https://doi.org/10.1177/10738584211021018

doi: 10.1177/10738584211021018 pubmed: 34088252

Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Yıldız Akar F, Komsuoglu Celikyurt I, Erden BF (2013) Involvement of serotonin receptor subtypes in the antidepressant-like effect of beta receptor agonist Amibegron (SR 58611A): an experimental study. Pharmacol Biochem Behav 105:12–16. https://doi.org/10.1016/j.pbb.2013.01.010

doi: 10.1016/j.pbb.2013.01.010 pubmed: 23380524

Treit D, Engin E, McEown K (2010) Animal models of anxiety and anxiolytic drug action. Curr Top Behav Neurosci 2:121–160. https://doi.org/10.1007/7854_2009_17

doi: 10.1007/7854_2009_17 pubmed: 21309109

Truppman Lattie D, Nehoff H, Neehoff S, Gray A, Glue P (2021) Anxiolytic effects of acute and maintenance ketamine, as assessed by the fear questionnaire subscales and the Spielberger State anxiety rating scale. J Psychopharmacol 35(2):137–141. https://doi.org/10.1177/0269881120953991

doi: 10.1177/0269881120953991 pubmed: 32900266

Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, Worley PF (1999) Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins. Neuron 23(3):583–592. https://doi.org/10.1016/S0896-6273(00)80810-7

doi: 10.1016/S0896-6273(00)80810-7 pubmed: 10433269

Unal G, Canbeyli R (2019) Psychomotor retardation in depression: A critical measure of the forced swim test. Behav Brain Res 372:112047. https://doi.org/10.1016/j.bbr.2019.112047

doi: 10.1016/j.bbr.2019.112047 pubmed: 31255672

Valle FP (1970) Effects of strain, sex, and illumination on open-field behavior of rats. Am J Psychol 83(1):103. https://doi.org/10.2307/1420860

doi: 10.2307/1420860 pubmed: 5465190

Walf AA, Frye CA (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2(2):322–328. https://doi.org/10.1038/nprot.2007.44

doi: 10.1038/nprot.2007.44 pubmed: 17406592 pmcid: 3623971

Wang Y, He W, Zhang H, Yao Z, Che F, Cao Y, Sun H (2020) mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress. J Affect Disord 272:398–408. https://doi.org/10.1016/j.jad.2020.03.104

doi: 10.1016/j.jad.2020.03.104 pubmed: 32553383

Widman AJ, McMahon LL (2018) Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci 115(13). https://doi.org/10.1073/pnas.1718883115

Yankelevitch-Yahav R, Franko M, Huly A, Doron R (2015) The forced swim test as a model of depressive-like behavior. J Vis Exp 97:52587. https://doi.org/10.3791/52587

doi: 10.3791/52587

Yilmaz A, Schulz D, Aksoy A, Canbeyli R (2002) Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71(1–2):341–344. https://doi.org/10.1016/S0091-3057(01)00693-1

doi: 10.1016/S0091-3057(01)00693-1 pubmed: 11812542

Youssef EA, Berry-Kravis E, Czech C, Hagerman RJ, Hessl D, Wong CY, Rabbia M, Deptula D, John A, Kinch R, Drewitt P, Lindemann L, Marcinowski M, Langland R, Horn C, Fontoura P, Santarelli L, Quiroz JA, FragXis Study Group (2018) Effect of the mGluR5-NAM Basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results. Neuropsychopharmacology 43(3):503–512. https://doi.org/10.1038/npp.2017.177

doi: 10.1038/npp.2017.177 pubmed: 28816242

Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23(4):801–811. https://doi.org/10.1038/mp.2017.255

doi: 10.1038/mp.2017.255 pubmed: 29532791 pmcid: 5999402

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA, Gould TD (2019) 2R,6R hydroxynorketamine exerts mGlu2/3 receptor-dependent antidepressant actions. Proc Natl Acad Sci 116(13):6441–6450. https://doi.org/10.1073/pnas.1819540116

doi: 10.1073/pnas.1819540116 pubmed: 30867285 pmcid: 6442605

Zanos P, Brown KA, Georgiou P, Yuan P, Zarate CA, Thompson SM, Gould TD (2023) NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. J Neurosci 43(6):1038–1050. https://doi.org/10.1523/JNEUROSCI.1316-22.2022

doi: 10.1523/JNEUROSCI.1316-22.2022 pubmed: 36596696 pmcid: 9908316

Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856. https://doi.org/10.1001/archpsyc.63.8.856

doi: 10.1001/archpsyc.63.8.856 pubmed: 16894061

Zhang LM, Zhou WW, Ji YJ, Li Y, Zhao N, Chen HX, Xue R, Mei XG, Zhang YZ, Wang HL, Li YF (2015) Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder. Psychopharmacology 232(4):663–672. https://doi.org/10.1007/s00213-014-3697-9

doi: 10.1007/s00213-014-3697-9 pubmed: 25231918

Zhang K, Yamaki VN, Wei Z, Zheng Y, Cai X (2017) Differential regulation of GluA1 expression by ketamine and memantine. Behav Brain Res 316:152–159. https://doi.org/10.1016/j.bbr.2016.09.002

doi: 10.1016/j.bbr.2016.09.002 pubmed: 27599619

Zhang B, Yang X, Ye L, Liu R, Ye B, Du W, Shen F, Li Q, Guo F, Liu J, Guo F, Li Y, Xu Z, Liu Z (2021) Ketamine activated glutamatergic neurotransmission by GABAergic disinhibition in the medial prefrontal cortex. Neuropharmacology 194:108382. https://doi.org/10.1016/j.neuropharm.2020.108382

doi: 10.1016/j.neuropharm.2020.108382 pubmed: 33144117

Zhang K, Xu T, Yuan Z, Wei Z, Yamaki VN, Huang M, Huganir RL, Cai X (2016) Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci Signal 9(458). https://doi.org/10.1126/scisignal.aai7884

Zomkowski AD, Santos AR, Rodrigues AL (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381(3):279–283. https://doi.org/10.1016/j.neulet.2005.02.026

doi: 10.1016/j.neulet.2005.02.026 pubmed: 15896484